![PDF) Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: An 8-week open-label extension study PDF) Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: An 8-week open-label extension study](https://i1.rgstatic.net/publication/327046225_Efficacy_and_safety_of_DFN-11_sumatriptan_injection_3_mg_in_adults_with_episodic_migraine_An_8-week_open-label_extension_study/links/5fb92e1e458515b7975cb5b7/largepreview.png)
PDF) Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: An 8-week open-label extension study
![These highlights do not include all the information needed to use SUMATRIPTAN INJECTION safely and effectively. See full prescribing information for SUMATRIPTAN INJECTION. SUMATRIPTAN injection, for subcutaneous useInitial U.S. Approval: 1992 These highlights do not include all the information needed to use SUMATRIPTAN INJECTION safely and effectively. See full prescribing information for SUMATRIPTAN INJECTION. SUMATRIPTAN injection, for subcutaneous useInitial U.S. Approval: 1992](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=sumatriptan-06.jpg&id=593165)
These highlights do not include all the information needed to use SUMATRIPTAN INJECTION safely and effectively. See full prescribing information for SUMATRIPTAN INJECTION. SUMATRIPTAN injection, for subcutaneous useInitial U.S. Approval: 1992
![PDF) DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment PDF) DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment](https://i1.rgstatic.net/publication/331803174_DFN-02_Sumatriptan_10_mg_Nasal_Spray_with_Permeation_Enhancer_for_the_Acute_Treatment_of_Migraine_A_Randomized_Double-Blind_Placebo-Controlled_Study_Assessing_Functional_Disability_and_Subject_Satisfa/links/5c8cf51745851564fae0f5b8/largepreview.png)
PDF) DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment
![US20060002989A1 - Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same - Google Patents US20060002989A1 - Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same - Google Patents](https://patentimages.storage.googleapis.com/a5/60/51/e8a1bd237b1a68/US20060002989A1-20060105-D00008.png)
US20060002989A1 - Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same - Google Patents
![Dabigatran Market to Witness Huge Growth by 2028 | Pfizer, Bayer Healthcare, GlaxoSmithKline, Boehringer Ingelheim – Energy Siren Dabigatran Market to Witness Huge Growth by 2028 | Pfizer, Bayer Healthcare, GlaxoSmithKline, Boehringer Ingelheim – Energy Siren](https://energysiren.co.ke/wp-content/uploads/2022/01/Global-Dabigatran-Market-Including-Key-Players-Market-Share.jpg)
Dabigatran Market to Witness Huge Growth by 2028 | Pfizer, Bayer Healthcare, GlaxoSmithKline, Boehringer Ingelheim – Energy Siren
![Sumatriptan Iontophoretic Transdermal System Reduces Treatment‐Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline – Results From a Randomized Controlled Trial - Bigal - 2015 - Headache: The Sumatriptan Iontophoretic Transdermal System Reduces Treatment‐Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline – Results From a Randomized Controlled Trial - Bigal - 2015 - Headache: The](https://headachejournal.onlinelibrary.wiley.com/cms/asset/4797e733-dbf5-4103-848a-bc2f56d81e2a/head.2015.55.issue-8.cover.jpg)